Abstract
Preclinical animal models of breast cancer provide the opportunity to identify chemopreventive drugs with single-agent activity as well as effective multi-modality regimens for primary as well as secondary prevention in high-risk persons. Our group has used the 7,12-dimethylbenz(a)anthracene (DMBA) mouse model of carcinogen-induced breast cancer to explore the clinical potential of two tyrosine kinase inhibitors and a nucleoside analog as chemopreventive agents. All three agents exhibited promising preclinical activity both as monotherapy and as components of combination therapy with the standard chemotherapy drug paclitaxel. The tumors developing despite chemoprevention were not only small and grew slowly, but they also displayed a uniquely more pro-apoptotic protein expression profile. Hence, our experimental chemopreventive drugs were capable of preventing the development of aggressive mammary gland tumors with an apoptosis-resistant protein expression profile.
Highlights
Over 1.5 million women are diagnosed with and over 0.5 million women die of breast cancer each year
The adverse impact of breast cancer on quality of life, productivity, and survival, as well as health care costs, have prompted intensive research efforts aimed at the identification of breast cancer prevention methods [3]
aromatase inhibitors (AIs) administered as adjuvant therapy after breast surgery were highly effective in reducing the incidence of breast cancer recurrence in women who are diagnosed with breast cancer [6]
Summary
Deniz Can GÜVEN1 , Cemal ORHAN2 , Kazim ŞAHİN2,* , Fatih M.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call